Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

BACKGROUND: Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable when darunavir 800 mg once daily was co-administered with cobicistat 150 mg once daily (as single agents or a fixed-dose combination) vs. with ritonavir 100 mg once daily....

Descripción completa

Detalles Bibliográficos
Autores principales: Tashima, Karen, Crofoot, Gordon, Tomaka, Frank L, Kakuda, Thomas N, Brochot, Anne, Van de Casteele, Tom, Opsomer, Magda, Garner, William, Margot, Nicolas, Custodio, Joseph M, Fordyce, Marshall W, Szwarcberg, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413526/
https://www.ncbi.nlm.nih.gov/pubmed/25926858
http://dx.doi.org/10.1186/1742-6405-11-39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413526/
https://www.ncbi.nlm.nih.gov/pubmed/25926858
http://dx.doi.org/10.1186/1742-6405-11-39

Ejemplares similares